Eli Lilly And Company ((LLY)), AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Eli Lilly and Company, in collaboration with AstraZeneca, is conducting a Phase 3 clinical study titled SUNRAY-02 to evaluate the efficacy and safety of Olomorasib in combination with standard care immunotherapy for patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC). The study aims to determine if Olomorasib, when combined with pembrolizumab or durvalumab, is more effective than the standard care combinations with placebos.
The study tests Olomorasib, an oral drug, alongside pembrolizumab and durvalumab, both administered intravenously. The goal is to improve treatment outcomes for patients with resected or unresectable KRAS G12C-mutant NSCLC.
This interventional study is randomized, double-blind, and placebo-controlled, with a parallel assignment model. The primary purpose is treatment-focused, ensuring unbiased results through participant and investigator masking.
The study began on March 27, 2025, with the latest update submitted on July 7, 2025. These dates are crucial for tracking the study’s progress and anticipated completion, which will inform future treatment protocols.
This update could positively impact Eli Lilly and AstraZeneca’s stock performance, as successful outcomes may enhance their market positions in the oncology sector. Investors should monitor developments closely, considering the competitive landscape of cancer treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.